In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EnteroMedics' obesity device fails to measure up in US trial – again

This article was originally published in Clinica

Executive Summary

EnteroMedics' share price has plunged 56% after reporting that its Maestro weight-loss device failed, for the second time, to meet its primary endpoint in a pivotal trial. However, the firm still plans to file a premarket approval (PMA) application with the US FDA in the second quarter. It is taking solace in the fact there was significant weight loss in patients treated with the device compared with a control group receiving sham therapy – although the effects was not as large as EnteroMedics had hoped for.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts